“Apremilast as an Off-Label Therapeutic Agent: A Comprehensive Review of Safety and Efficacy Data in the Literature for Combination Therapy and Inflammatory Dermatoses” (2021) SKIN The Journal of Cutaneous Medicine, 5(3), pp. 203–227. doi:10.25251/skin.5.3.2.